Actelion core earnings rise 9 percent, matching analyst poll

ZURICH (Reuters) – Actelion , Europe’s largest biotechnology company, said on Tuesday that 2015 core earnings rose 9 percent, matching analyst forecasts, as the company was helped by rising sales of a new drug to treat a deadly heart-lung disease. Core earnings were 814 million Swiss francs ($827.24 million), compared to analyst forecasts of 813 million francs. Product sales rose 4 percent to 2.042 billion francs, compared to the analyst forecast of 2.044 billion francs. After paten